Anixa Biosciences (Anixa Biosciences) Cash-to-Debt

: 146.90 (As of Jan. 2024)

View and export this data going back to 1989. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Anixa Biosciences's cash to debt ratio for the quarter that ended in Jan. 2024 was 146.90.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Anixa Biosciences could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Anixa Biosciences's Cash-to-Debt or its related term are showing as below:

ANIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4 Med: 903.27 Max: No Debt
Current: 146.9

During the past 13 years, Anixa Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.40. And the median was 903.27.

ANIX's Cash-to-Debt is ranked better than
81.4% of 1538 companies
in the Biotechnology industry
Industry Median: 6.745 vs ANIX: 146.90

Anixa Biosciences Cash-to-Debt Historical Data

The historical data trend for Anixa Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Anixa Biosciences Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Cash-to-Debt

No Debt

164.67

137.94

134.33

136.25

Anixa Biosciences Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt																132.55	136.24	136.55	136.25	146.90

Competitive Comparison

For the Biotechnology subindustry, Anixa Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anixa Biosciences Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cash-to-Debt falls into.

Anixa Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Anixa Biosciences's Cash to Debt Ratio for the fiscal year that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	23.844	/	(0.052	+	0.123)
	=	136.25

Anixa Biosciences's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	23.798	/	(0.054	+	0.108)
	=	146.90

Anixa Biosciences (NAS:ANIX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Anixa Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Anixa Biosciences (Anixa Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118

Website

https://www.anixa.com

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Executives

Amit Kumar	director, officer: Chief Executive Officer	C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani	officer: COO & CFO	12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr	director	6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk	director	3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan	director
David Cavalier	director	C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams	director	C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox	director	929 NOWITA PLACE, VENICE CA 90291
Andrea Belz	director	1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender	officer: Chief Operating Officer	900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman	officer: President and CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop	officer: Sr. Vice President-Engineering	C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson	director	20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams	director	C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747